|
End-of-day quote
Shanghai S.E.
25/08/2026
|
5-day change | 1st Jan Change | ||
| 18.41 CNY | +6.05% |
|
+2.79% | +4.48% |
| 08-24 | DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 24.54 | +34.48% | 7 | ||||||
| 58.57 | +83.09% | 16 | ||||||
| 4.606 | +68.12% | 15 | ||||||
| 3,035 | +17.61% | 10 | ||||||
| 33.09 | +39.55% | 12 | ||||||
| 121.52 | +28.93% | 9 | ||||||
| 327.88 | +64.35% | 8 | ||||||
| - | - | 1,415 | +208.12% | 1 | ||||
| 48.83 | +30.29% | 6 | ||||||
| 37.19 | +28.01% | 8 | ||||||
| 87.5 | +38.12% | 10 | ||||||
| 14.86 | +25.52% | 5 | ||||||
| 52.7 | +34.71% | 8 | ||||||
| 1,013.14 | +46.39% | 7 | ||||||
| - | 92.5 | +22.84% | 2 | |||||
| - | 5,100 | +40.5% | 2 | |||||
| Average | 716.68 | +50.67% | 8 | ||||||
| Weighted average by Cap. | 562.05 | +59.93% | 11 |
Select your edition
All financial news and data tailored to specific country editions
